Publications, Pharmaceutical

Improving Intranasal Sprays for Respiratory Viral Infections

Intranasal sprays have considerable potential for the treatment of viral infections such as the SARS-CoV-2 virus which enter via the upper airway.

Download Publication on intranasal sprays for respiratory viral infections
28 Jan 2022

This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

15 Jun 2020

Accelerating the development of COVID vaccines and therapeutics

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
1 Jun 2020

Aptar Pharma expert Q&A on digital health and connected drug delivery

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
26 May 2020

Aptar Pharma discusses Article 117 of the Medical Device Regulations

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
12 May 2020

Drug Delivery Systems & Services for Lifecycle Management of Crisis Medications ...

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
1 21 22 23 24 25 27

Request Access

Close

Requesting access to Improving Intranasal Sprays for Respiratory Viral Infections.

  • This field is for validation purposes and should be left unchanged.
Back To Top